Tag Archive for: immunology

Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize

/in

Awarded in recognition of excellence in research and innovation and contribution to scientific progress Reflects the revolutionary potential of Curve’s gene-encoded Microcycle® platform to unlock the therapeutic potential of intracellular targets Southampton, UK, 25 June 2025 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company building a pipeline of innovative cyclic peptide and […]

Read more

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

/in

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Read more

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer

/in

Revolutionary ‘off-the-shelf’ cancer vaccine designed to prevent the recurrence of oesophageal cancer ITOP1 to enter first-in-human Phase I/IIa clinical development in the VISTA study in H1 2025 Multicentre study to be conducted at four university cancer centres, aiming to raise the standard of care by reducing the recurrence of metastases and cancer-related deaths Oxford, UK […]

Read more

Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer

/in

Pioneering cancer immunology company Asgard strengthens leadership team as it progresses its lead asset AT-108 towards clinical trials Shane brings over two decades of expertise in immunology-driven drug discovery with a specialized focus on novel modalities AT-108 is a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses Lund, Sweden, […]

Read more

Medicxi Announces $40m investment in D3 Bio

/in

Investment will support development of a differentiated pipeline in oncology Most advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitor Data on lead asset D3S-001 to be presented at AACR on 8 April 2024  8 April 2024, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces an investment of […]

Read more